CRDF - NASDAQ
Cardiff Oncology, Inc.
$1.51
+7.5%Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
At a Glance
Live SnapshotCardiff Oncology, Inc. Management Team
Dr. Mark Erlander Ph.D.
Chief Executive Officer & Director
Compensation
$929,614
Mr. James E. Levine
Chief Financial Officer
Compensation
$674,750
Dr. Fairooz F. Kabbinavar FACP, M.D.
Chief Medical Officer
Compensation
$681,283
Dr. Tod Smeal Ph.D.
Chief Scientific Officer
Compensation
$2,686,374
Ms. Brigitte Lindsay
Senior Vice President of Finance
Mr. Charles Monahan R.Ph.
Senior Vice President of Regulatory Affairs
Ms. Elizabeth Anderson
Vice President of Finance & Administration
Cardiff Oncology, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.44M and sold $2.32M worth of CRDF shares, resulting in $873K of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
518.4K
1.44M
600.0K
2.32M
-873K
-$873K
Top Buyers
Pace Gary W
Director
$802K
White Lale
Director
$128K
Armitage James O
Director
$128K
Mohindru Mani
Director
$128K
Markin Rodney S
Director
$128K
Top Sellers
Sidhu Roger
Officer: Chief Medical Officer
$2.32M
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $873K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
SEC Filings
CRDF - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | April 29, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 27, 2023 | April 27, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 14, 2022 | June 09, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 10, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 04, 2020 | April 16, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 19, 2019 | June 06, 2019 | 2019 | |
DEF 14A DEF 14A 2019 N/A | December 18, 2018 | January 15, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 27, 2018 | May 30, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.